Search results
Results from the WOW.Com Content Network
Phage display is also a widely used method for in vitro protein evolution (also called protein engineering). As such, phage display is a useful tool in drug discovery. It is used for finding new ligands (enzyme inhibitors, receptor agonists and antagonists) to target proteins.
Later improvements of antibody phage display technology enables the display of millions of different antibody fragments on the surface of filamentous phage (better known as antibody phage library) and subsequent selection of highly specific recombinant antibodies to any given target. This technology is widely exploited in pharmaceutical ...
In immunology, affinity maturation is the process by which T FH cell-activated B cells produce antibodies with increased affinity for antigen during the course of an immune response. With repeated exposures to the same antigen, a host will produce antibodies of successively greater affinities .
The first step is to have phage display libraries prepared. This involves inserting foreign desired gene segments into a region of the bacteriophage genome, so that the peptide product will be displayed on the surface of the bacteriophage virion. The most often used are genes pIII or pVIII of bacteriophage M13. [5]
By providing information on mechanism of action, epitope mapping is a critical component in therapeutic monoclonal antibody (mAb) development. Epitope mapping can reveal how a mAb exerts its functional effects - for instance, by blocking the binding of a ligand or by trapping a protein in a non-functional state.
Combinatorial biology techniques generally begin with large numbers of peptides, which are generated and screened by physically linking a gene encoding a protein and a copy of said protein. This could involve the protein being fused to the M13 minor coat protein pIII, with the gene encoding this protein being held within the phage particle ...
As with other antibody mimetics, the idea behind developing the Affibody molecule was to apply a combinatorial protein engineering approach on a small and robust protein scaffold. The aim was to generate new binders capable of specific binding to different target proteins with almost good affinity, while retaining the favorable folding and ...
In 1989, Winter was a founder of Cambridge Antibody Technology, one of the early commercial biotech companies involved in antibody engineering. One of the most successful antibody drugs developed was HUMIRA ( adalimumab ), which was discovered by Cambridge Antibody Technology as D2E7, and developed and marketed by Abbott Laboratories .